Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …

While the understanding of the genomic aberrations that underpin chronic and acute
myeloid leukaemia (CML and AML) has allowed the development of therapies for these …

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …

Therapy resistance represents a major clinical challenge in acute myeloid leukemia (AML).
Here we define a 'MitoScore'signature, which identifies high mitochondrial oxidative …

Mitochondrial energetics and respiration have emerged as important factors in how cancer
cells respond to or evade apoptotic signals. The study of the functional connection between …

Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …

This systematic review identified various bioactive compounds which have the potential to
serve as novel drugs or leads against acute myeloid leukemia. Acute myeloid leukemia …

Malignant stem cells have long been considered a key therapeutic target in leukemia.
Therapeutic strategies designed to target the fundamental biology of leukemia stem cells …

Despite an increasing arsenal of anticancer therapies, many patients continue to have poor
outcomes due to the therapeutic failures and tumor relapses. Indeed, the clinical efficacy of …

Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical
problem. Using acute myelogenous leukemia (AML) patient-derived xenograft (PDX) models …